Chart - you can draw at the chart
Starting Amount
$
After
years
Dividend yield
%
Dividends reinvested
$
Discovery Laboratories Inc.
Type
Public
Traded as NASDAQ:DSCO
Industry Healthcare – biotechnology
Founded 1992
Headquarters Warrington, Pennsylvania, United States
Key people

John G. Cooper
(Chief Executive Officer, President, Chief Financial Officer, and Director)
Thomas F. Miller Ph.D.
(Chief Operating Officer)

Mr. John A. Tattory
(Chief Accounting Officer) (Dec 31, 2012)
Services Respiratory critical care
Revenue $ 510.00K (Sep 30, 2013)
Number of employees
119 (Sep 30, 2013)
Website www.discoverylabs.com

Discovery Laboratories, Inc (NASDAQ:DSCO) is an American company which was set up in 1992 and now is based in Warrington, Pennsylvania, developing drug products (pulmonary medicine) for patients with respiratory disease. The company joined an alliance with Laboratorios del Dr. Esteve, S.A.

The major products of the company are Surfaxin (based on its capillary aerosol-generating technology) and Aerosurf. Surfaxin is a synthetic, peptide-containing (KL4) surfactant, similar to pulmonary surfactant, which is naturally in the lung for normal respiratory function. The drug is delivered by its capillary aerosol-generating technology to the lung. Aerosurf is a drug-device combination to prevent respiratory distress syndrome (RDS) in premature infants. In addition, the company also provides Afectair devices (disposable aerosol-conducting airway connectors).

In November 2013, Discovery Laboratories began its phase II clinical program of aerosolized KL4 since U.S. Food and Drug Administration (FDA) had cleared the investigational new drug (IND) application. The phase II consists of two steps to evaluate the safety and tolerability of the drug and determine the optimal dose for premature infants with respiratory distress syndrome (RDS)

In October 2013, Discovery Laboratories received the agreement of updating Surfaxin (lucinactant) Intratracheal Suspension from the U.S. Food and Drug Administration (FDA) to prevent respiratory distress syndrome (RDS) in premature infants.

In September 2012, Discovery Laboratories started the four research projects to explore the KL4 surfactant technology for acute lung injury (ALI). These projects are funded through government-sponsored, biodefense-related initiatives under the Project Bioshield Act of 2004 and the Pandemic and All Hazards Preparedness Act of 2006.

Investment goal date:
Dividends reinvested
Discovery Laboratories Inc. DSCO report Q4 2015
Period
Date
Adjusted Actuals EPS
GAAP EPS
Q2 2016
2016-08-05
--
--
Q1 2016
2016-05-05
--
--
Q4 2015
2016-03-24
0.0000
0.0000
Q3 2015
2015-11-05
0.0000
-2.8000
Q2 2015
2015-08-10
0.0000
-1.8200
Q1 2015
2015-05-07
0.0000
-1.9600
Q4 2014
2015-03-16
0.0000
-1.6800
Q3 2014
2014-11-06
0.0000
-1.8200
Q2 2014
2014-08-05
0.0000
-1.6800
Q1 2014
2014-05-08
0.0000
-1.9600
There is presents forecasts or rating agencies and recommendation for investors about this ticker
Funds
Fund Name
Ticker shares
Major Shareholders
Name Relationship
Total Shares
Holding stocks
CAPETOLA ROBERT J
0.5200% (446025)
DSCO /
SEGAL ROBERT-MD
0.0500% (39415)
DSCO /
ROSENTHALE MARVIN E
0.0100% (6211)
DSCO /
COOPER JOHN G
0.0600% (47511)
DSCO / RMTI /
MAHADY JOSEPH M
0.0100% (6211)
ALB / DSCO /
PEACOCK BRUCE
0.0100% (6211)
LOPEZ DAVID L
0.0100% (8033)
DSCO /
Leone John R
0.0100% (11250)
DSCO / VPHM /
Amick W Thomas
0.0100% (10614)
DNDN / DSCO /
Katzer Charles F
0.0200% (20000)
DSCO /
Cole Kathy
0.0200% (13989)
DSCO /
Miller Thomas F
0.0200% (14110)
DSCO /
Tattory John A
0.0100% (6555)
DSCO /
Tattory John A
1.0400% (884215)
DSCO /
Hoy Thomas
0.0100% (10781)
DSCO /
Templeton Mary B Esq
0.0100% (9270)
DSCO /
Fraser Craig
2.3300% (1983690)
AEGR / DSCO /
Simonson Steven
0.0100% (6884)
DSCO /
% ()